Followers | 505 |
Posts | 10140 |
Boards Moderated | 0 |
Alias Born | 04/28/2014 |
![](https://investorshub.advfn.com/uicon/475374.png?cb=1683825270)
Thursday, August 23, 2018 1:16:34 PM
Recent RGNX News
- REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients • PR Newswire (US) • 06/24/2024 11:05:00 AM
- REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II • PR Newswire (US) • 06/18/2024 11:05:00 AM
- REGENXBIO Announces Leadership Transition • PR Newswire (US) • 06/12/2024 11:05:00 AM
- REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference • PR Newswire (US) • 06/05/2024 11:05:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 08:43:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 08:42:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 08:41:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 08:41:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 08:35:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:06:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/14/2024 08:22:51 PM
- REGENXBIO to Participate in Upcoming Investor Conferences • PR Newswire (US) • 05/10/2024 11:05:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:16:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:10:26 PM
- REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights • PR Newswire (US) • 05/08/2024 08:05:00 PM
- REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights • PR Newswire (US) • 05/01/2024 11:05:00 AM
- REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit • PR Newswire (US) • 04/24/2024 11:05:00 AM
- REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD • PR Newswire (US) • 03/28/2024 11:05:00 AM
- REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days • PR Newswire (US) • 03/27/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 12:00:31 PM
- REGENXBIO to Participate in Upcoming Investor Conferences • PR Newswire (US) • 03/11/2024 11:05:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/08/2024 11:09:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:05:43 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 03/07/2024 11:03:26 AM
- REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants • PR Newswire (US) • 03/07/2024 04:20:00 AM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM